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Abstract
In this review we will focus on the current status and views concerning the production of antibody
fragments and antibody fusion proteins by yeasts and filamentous fungi. We will focus on single-
chain antibody fragment production (scFv and VHH) by these lower eukaryotes and the possible
applications of these proteins. Also the coupling of fragments to relevant enzymes or other
components will be discussed. As an example of the fusion protein strategy, the 'magic bullet'
approach for industrial applications, will be highlighted.
Introduction
Antibodies (also called immunoglobulins) are glycopro-
teins, which specifically recognise foreign molecules.
These recognised foreign molecules are called antigens.
When antigens invade humans or animals, an immuno-
logical response is triggered which involves the produc-
tion of antibodies by B-lymphocytes. By this
immunological response, microorganisms, larger para-
sites, viruses and bacterial toxins can be rendered harm-
less. The unique ability of antibodies to specifically
recognise and bind with high affinity to virtually any type
of antigen, made them interesting molecules for medical
and scientific research.
In 1975 Köhler and Milstein developed the monoclonal
antibody technology [1] by immortalising mouse cell
lines that secreted only one single type of antibody with
unique antigen specificity, called monoclonal antibodies
(mAbs). With this technology, isolation and production
of mAbs against protein, carbohydrate, nucleic acids and
hapten antigens was achieved. The technology resulted in
a rapid development of the use of antibodies in diagnos-
tics (e.g. pregnancy tests; [2]), human therapeutics and as
fundamental research tools.
More applications outside research and medicine can be
considered, such as consumer applications. Examples are
the use of antibodies in shampoos to prevent the forma-
tion of dandruff [3] or in toothpaste to protect against
tooth decay caused by caries [4]. For these purposes large
quantities of antibodies are required. However, for these
applications on a larger scale there were some major prob-
lems concerning the expensive production system based
on mammalian expression, the difficulty of producing an-
tibodies in bulk amounts and the low stability and solu-
bility of some antibodies under specific (harsh)
conditions.
In this review we will discuss the possibilities of large-
scale production of antibodies and fragments thereof by
relevant expression systems. Requirements are that the
system used for production is cheap, accessible for genetic
modifications, easily scaled up for greater demands and
safe for use in consumer applications.
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First, structure and characteristics of antibodies and anti-
body fragments generated thereof will be discussed, fol-
lowed by the impact of recombinant DNA technology and
antibody engineering techniques on the generation and
modification of antibodies and antibody fragments. The
modification of antibodies is of major interest since
changes in their functionality and physico-chemical prop-
erties will broaden their application area. For most appli-
cations only the antigen-binding site of the native
antibody molecule is required and even preferred. By the
development of recombinant DNA technology and the in-
creasing knowledge on the structure of antibody mole-
cules created the opportunity to clone and engineer
smaller fragments of antibody genes [5,6] and subsequent
alter their functions, for example improve the affinity for
their antigen. Besides that, recombinant DNA technology
provides the possibility to generate fusion proteins or
'Magic bullets', consisting of an antibody fragment fused
to an effector molecule.
In this review the various expression systems for these type
of protein will be outlined. We will detail on using yeasts
and filamentous fungi as suitable expression systems for
antibody fragments and antibody fusion proteins.
Antibodies and their unique antigen binding 
domains
Whole antibodies
In vertebrates five immunoglobulin classes are described
(IgG, IgM, IgA, IgD and IgE), which differ in their function
in the immune system. IgGs are the most abundant im-
munoglobulins in the blood and these molecules have a
molecular weight of approximately 160 kDa. They have a
basic structure of two identical heavy (H) chain polypep-
tides and two identical light (L) chain polypeptides (Fig-
ure 1). The H and L chains, which are all β-barrels, are kept
together by disulfide bridges and non-covalent bonds (for
a review about antibody structure see [7]). The chains
themselves can be divided in variable and constant do-
mains. The variable domains of the heavy and light chain
(VH and VL) which are extremely variable in amino acid
sequences are located at the N-terminal part of the anti-
body molecule. VH and VL together form the unique anti-
gen-recognition site. The amino acid sequences of the
Figure 1
Schematical representation of the structure of a conventional IgG and fragments that can be generated thereof. The constant 
heavy-chain domains CH1, CH2 and CH3 are shown in yellow, the constant light-chain domain (CL) in green and the variable 
heavy-chain (VH) or light-chain (VL) domains in red and orange, respectively. The antigen binding domains of a conventional 
antibody are Fabs and Fv fragments. Fab fragments can be generated by papain digestion. Fvs are the smallest fragments with an 
intact antigen-binding domain. They can be generated by enzymatic approaches or expression of the relevant gene fragments 
(the recombinant version). In the recombinant single-chain Fv fragment, the variable domains are joined by a peptide linker. 
Both possible configurations of the variable domains are shown, i.e. the carboxyl terminus of VH fused to the N-terminus of VL 
and vice versa.
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remaining C-terminal domains are much less variable and
are called CH1, CH2, CH3 and CL.
Fc fragment
The non-antigen binding part of an antibody molecule,
the constant domain Fc mediates several immunological
functions, such as binding to receptors on target cells and
complement fixation (triggering effector functions that
eliminate the antigen). The Fc domain is not essential for
most biotechnical applications, relying on antigen bind-
ing. The Fc fragment, which is glycosylated, can have dif-
ferent effector functions in the different classes of
immunoglobulins.
Antigen binding region
The unique antigen-binding site of an antibody consists of
the heavy and light chain variable domains (VH and VL).
Each domain contains four conserved framework regions
(FR) and three regions called CDRs (complementarity de-
termining regions) or hypervariable regions. The CDRs
strongly vary in sequence and determine the specificity of
the antibody. VL and VH domains together form a binding
site, which binds a specific antigen.
Antibody fragments generated thereof
Several functional antigen-binding antibody fragments
could be engineered by proteolysis of antibodies (papain
digestion, pepsin digestions or other enzymatic approach-
es), yielding Fab, Fv or single domains (Figure 1).
Fab fragments
Fab fragments (fragment antigen binding) are the antigen-
binding domains of an antibody molecule, containing VH
+ CH1 and CL + VL. Between CL and CH1 an interchain di-
sulfide bond is present. The molecular weight of the het-
erodimer is usually around 50 kDa [8]. Fab fragments can
be prepared by papain digestions of whole antibodies.
Fv fragments
The minimal fragment (~30 kDa) that still contains the
whole antigen-binding site of a whole IgG antibody is
composed of both the variable heavy chain (VH) and var-
iable light chain (VL) domains. This heterodimer, called
Fv fragment (for fragment variable) is still capable of
binding the antigen [9]. Normally, native Fv fragments are
unstable since the non-covalently associated VL and VH
domains tend to dissociate from one another at low pro-
tein concentrations.
Single domains
Single domain antigen binding fragments (dAbs) or VHs
were generated in the past [10,11]. They have good anti-
gen-binding affinities, but exposure of the hydrophobic
surface of the VH to the solvent, which normally interacts
with the VL, causes a sticky behaviour of the isolated VHs.
It turned out to be difficult to produce them in soluble
form, although replacement of certain amino acids in-
creased solubility of these single domains (see also Llama
Heavy-chain antibody fragments) Besides that, their af-
finity for the antigen was much less compared with other
antibody fragments [12].
Heavy-chain antibodies in Camelidae
In 1993 Hamers-Casterman et al. [13] discovered a novel
class of IgG antibodies in Camelidae (camels, dromedaries
and llamas). These antibodies are devoid of light chains
and therefore called 'heavy-chain' IgGs or HCAb (for
heavy-chain antibody; Figure 2). HCAbs have a molecular
weight of ~95 kDa instead of the ~160 kDa for conven-
tional IgG antibodies. Their binding domains consist only
of the heavy-chain variable domains, referred to as VHHs
[14] to distinguish it from conventional VHs. Since the
first constant domain (CH1) is absent (spliced out during
mRNA processing due to loss of a splice consensus signal;
[15,16]), the variable domain (VHH) is immediately fol-
lowed by the hinge region, the CH2 and the CH3 domains.
Although the HCAbs are devoid of light chains, they have
an authentic antigen-binding repertoire. The current
knowledge about the genetic generation mechanism of
HCAbs is reviewed by Nguyen et al. [17,18].
Recombinant antibodies, antibody fragments 
and antibody fusion proteins
The development and applications of recombinant DNA
technology led to the design of several new antibodies and
antibody fragments. Firstly, functionalities of these pro-
teins may be altered resulting in novel and improved
functions. One of the possible applications of recom-
binant whole antibodies is the use in human therapeutics
(see also Recombinant whole antibodies). Secondly,
smaller antibody fragments may be synthesised having
the advantage over whole antibodies in applications re-
quiring tissue penetration and rapid clearance from the
blood or kidney. Moreover, the use of recombinant ex-
pression systems could also be the solution for large-scale
production of antibody (fragments).
Recombinant whole antibodies
The development of human(ised) antibody molecules is
mostly aimed at reduction of unwanted immunological
properties in medical applications [19]. Repeated doses of
foreign (murine) antibody molecules could lead to an im-
mune response in patients recognising the mouse anti-
body as foreign. This so-called HAMA (human anti-
mouse antibody) response can lead to severe health
problems.
Two strategies are developed to reduce the antigenicity of
therapeutic antibodies (see also [20]). One of these strat-
egies is chimerisation. In this case the constant murine do-Microbial Cell Factories 2003, 2 http://www.microbialcellfactories.com/content/2/1/1
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mains are replaced by human constant domains [21,22].
The second strategy is grafting of only the murine CDRs
onto existing human antibody framework regions, which
is called humanisation [22].
At present there are more than 10 recombinant antibodies
approved by the US Food and Drug Administration (FDA)
for use in medicine and many more are in a late stage of
clinical trials. FDA approved recombinant mAbs are e.g.
Herceptin™ (Genetech, San Francisco, CA), which targets
and blocks the growth factor Her2 on the surface of breast
cancer cells and Rituxan™ (IDEC Pharmaceuticals Inc.,
San Diego, CA) used against non-Hodgkin's lymphoma
(see for more examples [23,24]). The use of recombinant
antibodies for medical purposes does not require a cheap
large-scale production process per se, since only a limited
amount of pure preparations is needed.
Production of recombinant antibody fragments by Es-
cherichia coli
Much work on antibody fragment production has been
focussed on Escherichia coli as an expression system (re-
viewed in [25]). The advantage of this system is the ability
to produce proteins in relative large amounts. Besides
that, E. coli is easily accessible for genetic modifications,
requires simple inexpensive media for rapid growth and
they can easily be cultured in fermentors permitting large-
scale production of proteins of interest. Several antibody
fragments have been produced in functional form (e.g.
[8,9,26,27]) and expression of relevant gene segments
also permitted the production of the recombinant anti-
body fragments. The problem of stability has been tackled
by generation of single-chain Fv (scFv) or disulfide stabi-
lised Fv (dsFv) fragments.
Selection of antibody fragments with improved 
functionalities
In 1990 McCafferty et al. [28] showed that antibody frag-
ments could be displayed on the surface of filamentous
Figure 2
Schematical representation of the structure of a conventional IgG, a heavy-chain IgG antibody and the variable heavy-chain anti-
body fragment (VHH) that can be generated of the latter. Heavy-chain antibodies found in llama and camel are only composed 
of heavy-chains and lack the light chain completely, as shown in this Figure. The antigen-binding domain consists of only the VH 
domain, which is referred to as VHH (variable heavy-chain antibody fragment), to distinguish it from a normal VH. The constant 
heavy-chain domains CH1, CH2 and CH3 are shown in yellow, the constant light-chain domain (CL) in green and the variable 
heavy-chain (VH or VHH) or light-chain (VL) domains in red and orange, respectively.
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phages, called phage-display. This technology is based on
the fusion of the antibody variable genes to a phage coat
protein gene (e.g. [20]). After displaying an antibody frag-
ment on the protein surface of the phage, antigen specific
phages can be selected and enriched by multiple rounds
of affinity panning (e.g. reviewed in [29,30]). This tech-
nique makes it possible to select phages that bind almost
any antigen, including those previously considered to be
difficult, such as self-antigens or cell surface proteins.
Libraries can be prepared from variable genes isolated
from immunised animals, non-immunised sources (naïve
libraries, thus avoiding the need for immunisation) or
even (semi-) synthetic libraries can be constructed. The V
genes can be subjected to random mutagenesis, chain or
DNA shuffling methods [31], mimicking the natural hy-
permutation mechanism.
Single-chain Fv fragments and multimers
An attractive recombinant antibody fragment is the single-
chain Fv (scFv) fragment (reviewed in [32,33]). It has a
high affinity for its antigen and can be expressed in a vari-
ety of hosts [34]. These and other properties make scFv
fragments not only applicable in medicine (reviewed in
[35]), but also of potential for biotechnological applica-
tions. In the scFv fragment the VH and VL domains are
joined with a hydrophilic and flexible peptide linker,
which improves expression and folding efficiency [36,37].
Usually linkers of about 15 amino acids are used, of which
the (Gly4Ser)3 linker has been used most frequently [35].
Unfortunately, some scFv molecules have a reduced affin-
ity compared to the parental whole antibody or Fab mol-
ecule [12,38,39]. Besides that, scFv molecules can be
easily proteolytically degraded, depending on the linker
used [40]. With the development of genetic engineering
techniques these limitations could be practically over-
come by research focussed on improvement of function
and stability, as discussed in [32]. An example is the gen-
eration of disulfide-stabilised Fv fragments where the VH-
VL dimer is stabilised by an interchain disulfide bond
[38,41,42]. Cysteïnes are introduced at the interface be-
tween the VL and VH domains, forming a disulfide bridge,
which holds the two domains together (reviewed in [43]).
Dissociation of scFvs results in monomeric scFvs, which
can be complexed into dimers (diabodies), trimers (tria-
bodies) or larger aggregates ([44], reviewed in [45]). The
simplest designs are diabodies that have two functional
antigen-binding domains that can be either similar (biva-
lent diabodies) or have specificity for distinct antigens
(bispecific diabodies). These bispecific antibodies allow
for example the recruitment of novel effector functions
(such as cytotoxic T cells) to the target cells, which make
them very useful for applications in medicine (reviewed
in [46,47]).
Llama Heavy-chain antibody fragments (VHHs)
The other type of interesting antibody fragments are VHHs
(see Figure 2) comprising the smallest available intact an-
tigen-binding fragment (~15 kDa, 118–136 residues
[48,49]). The affinities found for VHHs were in the na-
nomolecular range and comparable with those of Fab and
single chain Fv (scFv) fragments [50,51]. Besides that
VHHs are highly soluble and more stable than the corre-
sponding derivatives of scFv and Fab fragments [50,52].
VHHs carry amino acid substitutions that make them more
hydrophilic and prevent the prolonged interaction with
BiP (Immunoglobulin heavy-chain binding protein),
which normally binds to the H-chain in the Endoplasmic
Reticulum (ER) during folding and assembly, until it is
displaced by the L-chain [53]. There are indications that
this increased hydrophilicity improves secretion of the
VHHs from the ER. Hence, production of VHHs in com-
mercially attractive microorganisms may be favourable.
Several ways are described to obtain functional VHHs:
from proteolysed HCAb of an immunised camelid, direct
cloning of VHH  genes from B-cells of an immunised
camelid resulting in recombinant VHHs or from naïve or
synthetic libraries [49]. VHHs with desired antigen
specificity could be selected by phage display (see Selec-
tion of antibody fragments with improved functionali-
ties). Using VHHs in phage display is much simpler and
more efficient as compared with Fabs or scFvs, since only
one domain needs to be cloned and expressed to obtain a
functional antigen-binding fragment [52,54].
As already noted before (see Antibody fragments gener-
ated thereof), classical VHs were difficult to produce in
soluble form. To improve their solubility and prevent
non-specific binding, residues located on the VL side of
VHs were replaced by 'VHH-like' residues, mimicking the
more soluble VHH  fragments. This process has been
termed camelisation [55–57] and these camelised VH frag-
ments, particularly those based on the human framework,
are expected to have significant advantages for therapeuti-
cal purposes in humans (reviewed in [58]).
Fusion proteins ('Magic bullets')
A completely new use of the binding capacity of antibody
fragments is the design of a fusion approach, in which an
effector protein is coupled to an antigen recognising anti-
body fragment. In human medicine this approach is re-
ferred to 'Magic bullet'. All kinds of molecules can be used
as effector molecule only limited by the imagination. The
gene encoding the effector may be directly fused to the
gene of the antibody fragment of interest, resulting in nov-
el bifunctional proteins [59]. Examples of the use of this
approach will be given in the section Antibody fragments
and antibody fusion proteins for large-scale applica-
tions and consumer products.Microbial Cell Factories 2003, 2 http://www.microbialcellfactories.com/content/2/1/1
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Applications of antibody fragments and antibody 
fusion proteins
Applications of antibody fragments in human medicine
The smaller the better
Most applications of recombinant antibody fragments are
related to diagnosis and therapy in human medicine,
which is especially focussed on the use of antibodies as
the ideal cancer-targeting reagent (reviewed in [19,60–
62]). For some clinical applications small antibody frag-
ments have advantages over whole antibodies. The small
size permits them to penetrate tissues and solid tumours
more rapidly than whole antibodies [63] which recently
also was shown for VHHs [64]. Smaller antibody frag-
ments have also a much faster clearance rate in the blood
circulation, which leads to differences of selectivity [63].
Nowadays there are also promising pre-clinical and clini-
cal trials with antibody fragments as diagnostic or thera-
peutical agents [61,65]. Another application of antibody
fragments is to treat viral infections with so-called intra-
bodies, which are intracellular antibodies synthesised by
the cell and targeted to inactivate specific proteins within
the cell [66].
'Magic bullets' in medicine
The use of bi-functional molecules in medicine is aimed
at delivery of a protein drug, which is only active where it
is required. It thereby limits the dose of the drug, resulting
in less side effects of the drug towards healthy tissue and/
or less immunogenic response to the protein drug itself.
Also the physical interaction between the target and the
effector molecule increases the potency of the effector. Fu-
sion proteins are ideal immuno agents for cancer diagno-
sis [67] and cancer therapeutics. An example is the use of
cancer-specific bi-functional antibodies targeting potent
cytotoxic molecules to tumour cells and subsequently
eliminate these tumour cells without harming healthy
cells [68].
Potential applications of VHHs
Specific applications of VHHs are foreseen in the following
direction:
VHHs as drug carriers
It is expected that VHHs are also applicable in diagnosis
and therapy in human medicine, especially when an eco-
nomically feasible production, small size and stability are
required (reviewed in [49]). Cortez-Retamozo et al. [64]
recently showed that VHHs specifically could be targeted
to tumour cells, which together with the possibility of
generation of bispecific VHH constructs [69] is of major in-
terest for cancer therapy.
VHHs as delivery carriers in the brain
Antibodies and many other water soluble compounds are
excluded from the brain by the blood-brain barrier (BBB),
thus making treatment of brain-related disease very diffi-
cult. Recently, Muruganandam et al. [70] showed that VHH
were able to selectively bind to and transmigrate across
the BBB in a human in vitro BBB model and partly in vivo
in mice. This property can be exploited for the develop-
ment of efficient antibody carriers suitable for delivery of
macromolecules across the human BBB and subsequently
for treatment of neurological diseases.
VHHs as potent enzyme inhibitors
Hypervariable regions in VHHs are on average longer than
those of VHs [71,72]. The extended hypervariable regions
of VHHs are capable of penetrating deep into the cleft of
active sites of enzymes, binding to novel epitopes that are
not recognised by conventional antibodies [51,73,74]. Be-
cause of this property VHHs may act as better potent en-
zyme inhibitors [51,75,76].
VHHs in consumer products
Since llama VHHs are very stable, even at high tempera-
ture, applications can be envisaged in which a high tem-
perature step is involved (e.g. pasteurisation), without
losing antigen-binding properties [50]. Recently it was
shown that VHHs could be used to prevent phage infection
in cheese production processes [77], by recognising a
structural protein of the phage, which is involved in recog-
nition of the host Lactococcus lactis.
Table 1: Extracellular production of antibody fragments in prokaryotic expression systems.
Strains Characteristics Food grade Production yields References
Lactobacillus zeae Gram+ yes scFv, ND* (secreted/cell-bound) [91]
Bacillus subtilis Gram+ yes 10 to 15 mg/L scFv (secreted) [143,144]
Streptomyces lividans Gram+ yes 1 mg/L Fv fragment (secreted) [145,146]
Staphylococcus carnosus Gram+ yes 5–10 mg/L VH domain (secreted) [147]
Proteus mirabilis Gram- no 40 to 200 mg/L scFv (secreted) [148,149]
Escherichia coli Gram- no Several fragments (inclusion bod-
ies/periplasmic space)
[25,34]
*ND = not determinedMicrobial Cell Factories 2003, 2 http://www.microbialcellfactories.com/content/2/1/1
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Antibody fragments and antibody fusion proteins for large-
scale applications and consumer products
Many additional applications can be envisaged if an inex-
pensive and simple production system is available, yield-
ing large amounts of antibody fragments that can be
purified easily. The highly specific antigen-binding ability
could be used for inactivating bacteria or specific enzymes
that can cause spoilage of food. Other suggested applica-
tions are the use in biosensors, treatment of wastewater
[78], industrial scale separation processes such as separa-
tion of chiral molecules [79], purification of specific com-
ponents (proteins) from biological materials or the use as
abzymes [80,81]. They have also been considered as com-
ponents of novel consumer goods with new improved
functionalities, in oral care and personal hygiene (e.g. in
toothpaste or mouthwashes [82]). For dental applications
antibody fragments can be coupled to enzymes to increase
the concentration of antimicrobials like hypothiocyanate
and hypohalites, for example glucose oxidase (GOX;
[83]), galactose oxidase (GaOX; [84]) or lactate oxidase
(LOX; [85]). Other examples are targeted bleach in laun-
dry washing (e.g. detergents containing antibodies cou-
pled to molecules that specifically remove difficult stains)
or the use in shampoos where antibodies act to prevent
dandruff by inhibiting growth of specific microorganisms
causing this [3].
Suitable expression systems for the large-scale 
production of antibody fragments and antibody 
fusion proteins
To be able to use antibody fragments and antibody fusion
proteins in these large scale applications, a suitable ex-
pression system has to be chosen. Several expression sys-
tems are available, both from prokaryotic (Table 1) and
eukaryotic (Table 2) origin. Our main interest goes out to
these systems that are able to economically produce large
amount of proteins into the culture medium. Several of
these systems can be considered as suitable (both from
prokaryotic and eukaryotic origin). Hereafter several of
these systems will be discussed, with an emphasis on yeast
and fungal systems.
Drawbacks using E. coli as a host for antibody fragment 
production
As described in the section Production of recombinant
antibody fragments by Escherichia coli, this micro-organ-
ism has shown to be a potential expression host for anti-
body fragments and fusion proteins. Although the general
production yields in shake-flask cultures are low (several
mg/L), in fermentation processes several g/L could be
obtained (reviewed in [86]). There are two possibilities of
antibody fragment production in E. coli, either by secre-
tion of the fragments into the culture medium and/or
periplasmic space (the compartment between the inner
and outer membrane) or preparation of inclusion bodies
with subsequent in vitro folding. However, both strategies
have disadvantages that make the use of this prokaryote
not attractive for the large-scale production of antibody
fragments and antibody fusion proteins. Firstly, the secre-
tion of folded and fully assembled fragments in the medi-
um or periplasmic space is often accompanied with cell
lysis and subsequent product loss. Secondly, 'toxicity' of
the antibody sequence and concomitant plasmid loss is
frequently observed, which hamper high production lev-
els (reviewed in [25]). Thirdly, expression of the frag-
ments in inclusion bodies, which often results in
insoluble protein aggregates [87], demands laborious and
cost-intensive in vitro refolding (denaturation and rena-
turation) and purification steps. Hence, the final yield of
fragments is only a small percentage of the protein that
was initially present in the inclusion bodies even though
purification steps are nowadays facilitated by affinity
Table 2: Higher eukaryotic expression systems for heterologous protein production and possible advantages and disadvantages of the 
expression system.
Expression systems Ease of molecular 
cloning
upscaling Economic 
feasibility1
Pathogenic 
contaminants2
References3
Mammalian cells + +/- + + [59,150–154]
Insect cells ++ + + + [155–160]
Plants ++ +++ ++ ++ [92,93,161,162]
Transgenic animals* +/- +++ +/- +/- [163–166]
Yeasts +++ +++ +++ +++ See references in section 
Production of antibody 
fragments by lower 
eukaryotes.
Filamentous fungi +++ +++ +++ +++ [4,123,128]
+++ = excellent, ++ = good, + = sufficient, +/- = poor. * With transgenic animals in this context is mentioned the production of antibodies or anti-
body fragments in the milk of transgenic animals, for example rabbits, sheep, goats or cows 1 With economical feasibility is mentioned the time and 
cost of molecular cloning, upscaling and downstream processing (purification). 2 Pathogenic contaminants like viruses or pyrogens. 3 Articles dealing 
with production of antibodies, antibody fragments and antibody fusion proteins.Microbial Cell Factories 2003, 2 http://www.microbialcellfactories.com/content/2/1/1
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chromatography using C-terminal polypeptide tails, like
poly-His6 or FLAG [88,89]. Recently, production of solu-
ble and functional scFv by E. coli could be increased by im-
proving disulfide bond formation activity in the
cytoplasm, using mutants and overexpression of di-
sulfide-bond isomerase [90]. Finally, E. coli is unable to
carry out eukaryotic post-translational modifications and
is therefore not suitable when glycosylation of antibody
fragments or more importantly the fusion proteins is
required.
Alternative prokaryotic expression systems
E. coli is not the only available prokaryotic expression sys-
tem, although it is rather dominant in the field. Alterna-
tive prokaryotic expression systems are available for
antibody fragment production (Table 1). However, these
will encounter similar limitations as E. coli, even though
most organisms described in Table 1 secrete the investigat-
ed antibody fragment into the culture medium. A field
where production of antibody fragments in prokaryotic
cells could still be interesting, is in food grade organisms
used for delivery passive immunisation in humans, by
means of functional foods. In a recent article, Kruger et al.
[91] reported the production of scFv antibody fragments
against Streptococcus mutans by the Gram positive food
grade bacteria Lactobacillus zeae. In experimental animals
a decrease of S. mutans and reduced development of caries
was observed.
Eukaryotic expression systems
Also several eukaryotic systems can be envisaged for large-
scale production of antibody fragments and antibody fu-
sion proteins (see also [34]), like mammalian cells, insect
cells, plants, transgenic animals and lower eukaryotes (see
Table 2).
The production of therapeutical whole antibodies is well
established in mammalian cells. However, large-scale pro-
duction is expensive and time-consuming.
'Plantibodies' can be produced in several plant target or-
gans (reviewed in [92]). Roots, storage organs (seeds and
tubers) and fruiting bodies can be suitable for mass oral
(edible) applications (see [93] and references therein). Ex-
pression of scFv in transgenic plants has been proposed as
a way to produce and store pharmaceutical antibodies
[94,95] and as means to block physiological processes in
the plant itself [96] or establish plant pathogen resistance
[97]. Plants show several advantages as large-scale anti-
body production systems, like the ease and low costs of
growing plants, even in large quantities. However, the
generation of transgenic plants that express antibodies is
a time consuming process and the downstream processing
to isolate the expressed antibodies from the plant parts is
relatively expensive and laborious.
Production of antibody fragments by lower eukaryotes
An attractive possibility for the cost-effective large-scale
production of antibody fragments and antibody fusion
proteins are yeast or fungal fermentations. Large-scale fer-
mentation of these organisms is an established technolo-
gy already used for bulk production of several other
recombinant proteins and extensive knowledge is availa-
ble on downstream processes. Besides that, yeasts and fil-
amentous fungi are accessible for genetic modifications
and the protein of interest may be secreted into the culture
medium. In addition, some of their products have the so-
called GRAS (Generally Regarded As Safe) status and they
do not harbour pyrogens, toxins or viral inclusions.
Methylotrophic and other yeasts
The methylotrophic and other yeasts like Candida boidinii,
Hansenula polymorpha, Pichia methanolica and Pichia pas-
toris are well known systems for the production of heter-
ologous proteins (reviewed in [98]). High levels of
heterologous proteins (milligram-to-gram quantities) can
be obtained and scaling up to fermentation for industrial
applications is possible [99–101].
Especially the P. pastoris system is used in several industri-
al-scale production processes [102]. Ridder et al. [103]
were the first to report the expression of a scFv fragment
by P. pastoris. From then on several papers reported about
the use of P. pastoris for the production of recombinant
antibodies and fragments thereof [104,105]. In shake-
flask cultures a level of 250 mg/L scFv was obtained [106]
and Freyre et al. [107] were able to obtain even an expres-
sion level of 1.2 g/L scFv fragment under fermentation
conditions. However, Cupit et al. [108] also showed that
the production of antibody fragments by P. pastoris is not
always a success story.
Based on the described results the commercial recom-
binant antibody production by P. pastoris is promising.
However, products currently obtained from P. pastoris are
not regarded as GRAS, which may limit its use.
Wood et al. [109] were the first to report the production of
mouse IgM by the baker's yeast S. cerevisiae, although only
unassembled chains were detected in the culture medium.
However, the production of Fab fragments was possible as
was first shown by Horwitz et al. [110]. Although the ob-
tained levels were low, functional Fab fragments were se-
creted in the culture medium. Davis et al. [111] expressed
scFv antibody fragments in Schizosaccharomyces pombe.
Studies on the scFv production in the non conventional
yeasts Yarrowia lipolytica and Kluyveromyces lactis resulted
in 10–20 mg/L functional and soluble anti-Ras scFv [112].Microbial Cell Factories 2003, 2 http://www.microbialcellfactories.com/content/2/1/1
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Filamentous fungi: Trichoderma reesei and Aspergillus spp
Filamentous fungi, in particular species from the genera
Trichoderma and Aspergillus have the capacity to secrete
large amounts of proteins, metabolites and organic acids
into their culture medium. This property has been widely
exploited by the food and beverage industries where com-
pounds secreted by these filamentous fungal species have
been used for decades. This has led to the GRAS status for
some of their products. Filamentous fungi like A. awamori,
A. niger and A. oryzae are therefore suitable organisms for
the production of commercially interesting homologous
and heterologous proteins [113–115]. Strategies to im-
prove protein secretion by filamentous fungi are exten-
sively reviewed in [116–119].
Production strains of Trichoderma reesei (Hypocrea jecorina)
have an exceptional secretion capacity up to 35 g protein/
L, where half of the secreted protein consists of the cellu-
lase cellobiohydrolase I (CBH1; [120]). Therefore, Tri-
choderma  is considered as an excellent host for the
production of heterologous proteins (reviewed in
[121,122]). Nyyssönen et al. [123] reported a production
of 1 mg/L in shake-flasks of Fab antibody fragments by T.
Reesei Rut-C30. More strikingly, when the Fab antibody
fragment chain was fused to the core-linker region of
CBH1, a production level of 40 mg/L in shake-flasks and
150 mg/L in bioreactor cultivations was obtained
[123,124].
The use of S. cerevisiae and A. awamori for the 
large-scale production of antibody fragments 
and fusion proteins
In our own laboratory at TNO Nutrition and Food Re-
search in Zeist (The Netherlands) and in collaboration
with Unilever Research Vlaardingen (The Netherlands) re-
search on antibody fragment production in S. cerevisiae
and A. awamori has been carried out [125,126]. The aim
of this project was a detailed comparison of both
expression systems, in relation to their possible large-scale
production process of antibody fragments and fusion pro-
teins. In the framework of this collaboration also a new A.
awamori  expression system, based on xylose induction
was developed [127].
The use of S. cerevisiae and A. awamori for the large-
scale production of scFv
To investigate the feasibility of a large-scale cost-effective
process for the extracellular production of (functional-
ised) scFv fragments initially S. cerevisiae was used. How-
ever, it was shown that S. cerevisiae was a poor host for the
production of scFv, since the secretion of scFv was ham-
pered by improper folding of the fragments, because large
aggregates were formed in the ER and vacuolar-like or-
ganelles. It was hypothesised that the exposure of the hy-
drophobic surfaces on the VL and VH chains of scFv plays
an important role in the accumulation of scFv in the cell
[128]. Shusta et al. [129] reported the increase of scFv pro-
duction up to 20 mg/L in S. cerevisiae by optimising the ex-
pression system by overexpression of two ER resident
chaperones and reduction of growth temperature. Kauff-
man et al. [130] showed that overexpression of scFv in S.
cerevisiae resulted in cellular stress, displayed by decreased
growth rates and induction of the Unfolded Protein Re-
sponse (UPR). It was hypothesised that a functional UPR
was required to decrease the malfolded scFv in the ER,
leading to a recovery from cell stress.
As further improved levels were desired also a fungal ex-
pression system was considered [4]. In shake-flask cul-
tures a production level of 10 mg/L was achieved by using
A. awamori as production host. As secretion of a heterolo-
gous protein can be greatly enhanced by fusing it to a "car-
rier" protein such as glucoamylase (GLA; [117,118]), also
this fusion-approach was employed. Analysis of the cul-
ture medium of transformants carrying the fusion con-
struct revealed a production of approximately 50 mg/L
scFv in the culture medium [4]. Several commercially in-
teresting scFv fragments were investigated for their ability
to be produced by A. awamori using the GLA-fusion strat-
egy. The results showed that the production levels differed
significantly between the different scFv transformants. In-
terestingly, in some cases increased levels of scFv detected
in the culture medium corresponded to an increase of
transcription level of the ER chaperone BiPA [131], indi-
cating that the antibody fragments, like in S. cerevisiae,
may have problems with correct folding and aggregate in
the fungal cell.
To increase production levels, successful 10 L and 1,5 ×
104 L scale fermentations were carried out resulting in 200
mg/L scFv under optimal conditions. However, variable
amounts of scFv dimers and other multimers were ob-
served. Recent fermentation experiments performed by
Sotiriadis et al. [132] showed that the highest scFv level
was observed when induction was started in the late expo-
nential phase. An increase of the carbon and nitrogen
source concentrations and a decreased of the concentra-
tion of the inducer, resulted in increased product yields.
Production of Llama VHH antibody fragments by S. cerevi-
siae and A. awamori
Although the production of scFv fragments by S. cerevisiae
and A. awamori was successful, levels up to several g/L
were not achieved. Possibly the hydrophobic regions of
the scFv, responsible for keeping the variable regions of
the heavy and light chains together, could also interact
with other molecules in the cell. Aggregation of scFv in S.
cerevisiae may result in accumulation and subsequent deg-
radation (of a part) of the antibody fragment molecules
[128] as frequently observed when expressing heterolo-Microbial Cell Factories 2003, 2 http://www.microbialcellfactories.com/content/2/1/1
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gous proteins that exhibit hydrophobic surfaces [133]. In-
terestingly, antibody fragments devoid of these
hydrophobic surfaces could be obtained from camels,
dromedaries and llamas (VHHs, see Llama Heavy-chain
antibody fragments (VHHs) and [13]), providing an op-
tion to improve production levels in relevant microorgan-
isms [126].
VHHs could be produced in E. coli up to levels of 6 mg/L,
were found to be extremely stable, highly soluble and re-
acted specifically and with high affinity with antigens
[52]. VHHs were produced in S. cerevisiae at levels over 100
mg/L in shake-flask cultures [134], although considerable
amounts of VHHs were detected intracellularly. From a 1,5
× 104 L fed-batch fermentation, 1.3 kg of VHHs was ob-
tained, which clearly showed that these fragments could
be produced in this host more efficiently than scFv frag-
ments [135]. For a cost-effective large-scale process for the
production of VHHs in S. cerevisiae further improvement is
required. Van der Linden et al. [54] showed that produc-
tion of VHHs by S. cerevisiae could be improved by DNA
shuffling techniques, in which three homologous VHH
genes were randomly fragmentated and reassembled
subsequently.
Based on the fact that A. awamori performed superior for
scFv also the possibility of VHH production by A. awamori
was investigated. As a model VHHs against the hapten RR6
were chosen [134]. Gene fragments coding for anti-RR6
VHHs were cloned in an expression vector containing the
highly inducible endoxylanase promoter. Recent experi-
ments (Joosten et al. submitted) showed that functional
VHHs could be produced in the culture medium in shake-
flask cultures, albeit at relatively low levels. For further op-
timisation a carrier strategy and controlled fermentations
will be carried out.
Production of 'Magic bullets' by A. awamori
A major research interest is the production of fusion pro-
teins or 'Magic bullets', consisting of an antibody frag-
ment (scFv or VHH  fragment) fused to an enzyme of
interest. In our laboratory research has been carried out
with a few examples of scFv fragments coupled to glucose
oxidase (GOX). GOX is already for many years an interest-
ing enzyme for coupling to antibodies for killing cells
[136]. A scFv, which recognises for example oral Strepto-
mycetes, when fused to GOX, which is an antimicrobial en-
zyme, may kill bacteria by generation of the bactericidal
hydrogen peroxide. In activity assays it was shown that the
fusion protein produced by A. awamori was functional,
both in binding to the antigen and GOX activity [4].
In the detergent industry enzymatic bleaching may be a
good alternative to the current chemical bleaching used.
To make these laundry-cleaning products more effective,
the production of Magic bullets by filamentous fungi or
yeasts is of interest. An enzyme coupled to an antibody
fragment recognising persistent stains from e.g. azo-dyes
[134] results in a more directed bleaching process, result-
ing in lower amounts of required detergent, reduction of
harmful effects of the enzyme to the textile and lower en-
vironmental burden (see Figure 3).
Currently we are investigating the feasibility of produc-
tion of VHH-enzyme fusions by A. awamori. One of the
VHHs used is a model llama VHH, recognising the azo-dye
Reactive Red 6 (RR6 [134]). As a bleaching enzyme, the
Arthromyces ramosus peroxidase (ARP) [137,138] was ge-
netically linked to the VHH fragment. This peroxidase uti-
lises hydrogen peroxide to catalyse the oxidation of a wide
range of organic and inorganic compounds, which makes
the enzyme suitable for use in bleaching processes [139].
ARP alone could be produced in high amounts by A.
awamori (800 mg/L; Lokman et al. submitted). Prelimi-
nary results showed the feasibility of fusion protein pro-
duction by A. awamori, yielding high levels of ARP-VHH
fusion protein in controlled fermentation experiments
(Joosten et al. manuscript in preparation). The fusion pro-
tein showed both ARP activity and azo-dye binding
activity.
In future experiments VHHs fragments can be replaced by
other more relevant antibody fragments, for example
those binding tomato or blood spots. Also the peroxidase
part of the fusion can be further optimised.
Conclusions and future prospects
Recent developments in the fields of antibody engineering
and expression systems have enabled the engineering and
production of antibodies and antibody fragments for a
wide variety of applications. A lot of examples are already
mentioned, but presumably more applications can be en-
visaged. The development of the 'Magic bullet' approach
will even increase the interest in antibodies and their re-
lated products, also for applications in human medicine.
A recently envisioned application that is of much interest,
is the use of antibody fragments in micro-arrays. Antibody
arrays can be used for proteomic analysis by comparing
the differences in presence of proteins in healthy and dis-
eased cells. For this purpose antibody fragments derived
from large phage-antibody libraries can be used as probes
to capture proteins on chips in a high-throughput system
(reviewed in [140,141]). In this respect, VHHs fragments
are of great interest, due to their simple and stable
structure.
In this review we evaluated whether the yeast S. cerevisiae
and the filamentous fungus A. awamori are suitable ex-
pression systems for the large-scale production of anti-
body fragments and antibody fusion proteins. AlthoughMicrobial Cell Factories 2003, 2 http://www.microbialcellfactories.com/content/2/1/1
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A. awamori is not the best expression system for the pro-
duction single antibody domains (scFv and VHH  frag-
ments), in particular for the production of antibody
fusion proteins filamentous fungi offer significant poten-
tial. In particular in those cases where specific post-trans-
lational modification (e.g. N-glycosylation) is required for
functional expression of the effector protein (also in rela-
tion to pharmaceutical applications). In contrast to S. cer-
evisiae, filamentous fungi do not show extensive
hyperglycosylation [142].
Both the scFv-GOX as well as results from ARP-VHH fusion
proteins showed that the filamentous fungal system is a
promising candidate for the production of antibody fu-
sion proteins. In the future production of other fusion
proteins can be investigated in this or other fungal expres-
sion systems, allowing a potential breakthrough for anti-
body technology in producing large amounts of specific
recognition units coupled to effector molecules for con-
sumer applications.
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Figure 3
Schematical example of the 'Magic bullet' approach in consumer applications, where an antibody fragment (in this case a llama 
variable heavy-chain antibody fragment; VHH) recognising a spot on textile, is coupled to an effector molecule (in this case A. 
ramosus peroxidase; ARP). ARP is a peroxidase, which utilises hydrogen peroxide to catalyse the oxidation of a wide range of 
organic and inorganic compounds, which makes the enzyme suitable for use in bleaching processes [139].
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